文献速递流行病学与生物统计真实世界研究与卫生经济

mRNA-1273疫苗对B.1.1.7和B.1.351变异株及重症COVID-19的真实世界有效性

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
PubMed 文献 · Nat Med · 2021-07-09

在卡塔尔以工作年龄成人为主的人群中,采用匹配的检测阴性病例对照设计评估mRNA-1273疫苗对B.1.1.7和B.1.351变异株及重症COVID-19的真实世界有效性。结果显示单剂后对B.1.1.7感染有效性88.1%,对B.1.351为61.3%;两剂后分别达100%和96.4%,对重症COVID-19两剂后有效性95.7%。

要点

  • 单剂mRNA-1273对B.1.1.7感染有效性88.1%,对B.1.351为61.3%。
  • 两剂后对B.1.1.7感染有效性100%,对B.1.351为96.4%。
  • 两剂后对任何重症、危重或致死性COVID-19有效性95.7%。

核心结论

  • mRNA-1273疫苗对B.1.1.7和B.1.351感染(无论有无症状)及COVID-19住院和死亡高度有效,即使单剂后亦然。

研究设计与样本

  • 在卡塔尔以工作年龄成人为主的人群中,采用匹配的检测阴性病例对照设计评估mRNA-1273疫苗真实世界有效性。

主要发现

  • 第一剂后2周内疫苗有效性可忽略,但在第二剂接种前的第三和第四周快速上升。
  • 第一剂后≥14天但未接种第二剂时,对B.1.1.7感染有效性88.1%(95%CI:83.7-91.5%),对B.1.351为61.3%(95%CI:56.5-65.5%)。
  • 第二剂后≥14天,对B.1.1.7感染有效性100%(95%CI:91.8-100.0%),对B.1.351为96.4%(95%CI:91.9-98.7%)。
  • 对任何SARS-CoV-2感染(主要为B.1.1.7和B.1.351)所致任何重症、危重或致死性COVID-19,第一剂后有效性81.6%(95%CI:71.0-88.8%),第二剂后95.7%(95%CI:73.4-99.9%)。

临床怎么用

  • 支持在变异株流行地区使用mRNA-1273疫苗,单剂即可提供对重症COVID-19的显著保护,两剂后对B.1.1.7和B.1.351感染保护极高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021. PMID: 34244681. doi:10.1038/s41591-021-01446-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。